Northwestern Mutual Wealth Management Co. Has $39.16 Million Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

Northwestern Mutual Wealth Management Co. raised its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 1.5% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 423,894 shares of the medical research company’s stock after purchasing an additional 6,093 shares during the period. Northwestern Mutual Wealth Management Co. owned 0.07% of Edwards Lifesciences worth $39,155,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in EW. Crewe Advisors LLC acquired a new stake in shares of Edwards Lifesciences in the first quarter worth $28,000. First Community Trust NA acquired a new stake in shares of Edwards Lifesciences in the second quarter worth $29,000. Riverview Trust Co acquired a new stake in shares of Edwards Lifesciences in the first quarter worth $34,000. Webster Bank N. A. acquired a new stake in shares of Edwards Lifesciences in the second quarter worth $39,000. Finally, Versant Capital Management Inc grew its stake in shares of Edwards Lifesciences by 206.3% in the second quarter. Versant Capital Management Inc now owns 484 shares of the medical research company’s stock worth $45,000 after acquiring an additional 326 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently commented on EW shares. Deutsche Bank Aktiengesellschaft reduced their target price on Edwards Lifesciences from $103.00 to $85.00 and set a “buy” rating for the company in a research report on Thursday, July 25th. TD Cowen cut Edwards Lifesciences from a “buy” rating to a “hold” rating and reduced their target price for the stock from $100.00 to $70.00 in a research report on Thursday, July 25th. StockNews.com cut Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Thursday, July 25th. Canaccord Genuity Group reduced their target price on Edwards Lifesciences from $85.00 to $77.00 and set a “hold” rating for the company in a research report on Thursday, July 25th. Finally, Robert W. Baird cut Edwards Lifesciences from an “outperform” rating to a “neutral” rating and reduced their target price for the stock from $102.00 to $70.00 in a research report on Thursday, July 25th. Sixteen equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $79.82.

Edwards Lifesciences Trading Down 0.9 %

NYSE:EW opened at $65.99 on Tuesday. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12. The company has a quick ratio of 2.87, a current ratio of 3.71 and a debt-to-equity ratio of 0.08. The business has a 50 day moving average price of $67.34 and a two-hundred day moving average price of $81.69. The company has a market cap of $39.77 billion, a P/E ratio of 28.44, a price-to-earnings-growth ratio of 2.80 and a beta of 1.13.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Wednesday, July 24th. The medical research company reported $0.70 earnings per share for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. The firm had revenue of $1.63 billion during the quarter, compared to the consensus estimate of $1.65 billion. During the same quarter in the prior year, the firm posted $0.66 EPS. The business’s revenue was up 6.7% on a year-over-year basis. As a group, analysts expect that Edwards Lifesciences Co. will post 2.71 EPS for the current fiscal year.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 11th. The stock was sold at an average price of $66.77, for a total transaction of $333,850.00. Following the completion of the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at approximately $3,133,916.72. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, VP Daveen Chopra sold 1,250 shares of the stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total value of $87,437.50. Following the completion of the sale, the vice president now owns 29,333 shares of the company’s stock, valued at approximately $2,051,843.35. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction that occurred on Wednesday, September 11th. The shares were sold at an average price of $66.77, for a total value of $333,850.00. Following the completion of the sale, the vice president now directly owns 46,936 shares of the company’s stock, valued at approximately $3,133,916.72. The disclosure for this sale can be found here. Insiders sold a total of 16,250 shares of company stock valued at $1,218,138 in the last quarter. 1.29% of the stock is currently owned by insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.